血脂康对冠心病患者介入治疗后高敏C反应蛋白的影响  

Effects of Xuezhikang on blood levels of hs-CRP in patients with CHD after percutaneous coronary intervention

作　　者：刘鹏[1] 卢长青[2] 宋文翔[2] 邱春光[3] 黄斌[2] 张文学[2] 

机构地区：[1]河南省胸科医院心内科,郑州450003 [2]河南省中医院急诊科,郑州450002 [3]郑州大学第一附属医院心内科,郑州450052

出　　处：《郑州大学学报（医学版）》2009年第1期154-156,共3页Journal of Zhengzhou University(Medical Sciences)

基　　金：河南中医学院苗圃工程基金资助项目20060202

摘　　要：目的:观察冠心病稳定型心绞痛患者介入治疗术前口服血脂康对高敏C反应蛋白的影响。方法:纳入冠心病稳定型心绞痛拟行经皮冠状动脉介入治疗(PCI)的74例患者,按照就诊顺序分为血脂康组(n=35例)和对照组(n=39例),2组患者性别、年龄等临床资料相似,具有可比性。血脂康组患者术前在常规治疗的基础上口服血脂康1200mg/d,共1周,对照组除未服血脂康外其他治疗均与血脂康组相同。2组患者分别于术前至术后5d每d采集空腹静脉血3mL,采用速率散射比浊法定量分析高敏C反应蛋白,并检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)水平。结果:PCI术后2组患者高敏C反应蛋白均显著升高,血脂康组高敏C反应蛋白升高幅度显著低于对照组。2组患者治疗前后血脂水平差异无统计学意义。结论:冠心病患者PCI术前预服血脂康可显著减少术后高敏C反应蛋白的升高幅度。Aim ： To investigate the effects of Xuezhikang on blood levels of high sensitive C-creative protein（hs-CRP） in patients with CHD after pcrcutaneous coronary intervention （PCI）. Methods：Seventy-three patients with chronic stable angina scheduled for PC1 were enrolled in the study. Patients were consecutively assigned to Xuezhikang-treated group （ n = 35 ） or control group （n = 39） before 7 days of the procedure. There were no difference between the two groups at age,sex and other elinical characteristics. In addition to conventional treatment for these two groups,the Xuezhikang group received oral Xuezhikang （ 1 200 mg/d, for 7 days） ;while patients in control group were given the same cure as the Xuezhikang group except Xuezhikang. Fasting venous blood of 3 mL were collected from each patient at baseline and every day after the procedure for five （lays. Serum hs-CRP levels were quantitative analysised, and compared statistically. Results：Detection of hs-CRP was significantly higher after the procedure compared with baseline in two groups. The extension lower in the Xuezhikang-treated compared with the placebo group. Conclusion ： Pretreatment with Xuezhikang 1 200 mg/d for 7 days significantly reduce the increasing extension of hs-CRP levels in patients with CHD after PCI.

关 键 词：血脂康 高敏C反应蛋白 经皮冠状动脉成形术 

分 类 号：R541.4[医药卫生—心血管疾病]